Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109314 - FIBROBLAST GROWTH FACTOR 21 (FGF21) GENE THERAPY


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2019/082601 P6075726PCT
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
26 November 2019 26 November 2018
Applicant
UNIVERSITAT AUTONOMA DE BARCELONA
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
a. forming part of the international application as filed:
in the form of an Annex C/ST.25 text file.
on paper or in the form of an image file.
b. furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
c. furnished subsequent to the international filing date for the purposes of international search only:
in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.
In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3.
Additional comments:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No. ____________
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     C07K 14/50 (2006.01)i; A61K 48/00 (2006.01)i; C12N 15/86 (2006.01)i; C12N 15/864 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07K; A61K; C12N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
Y
VERONICA JIMENEZ ET AL, "FGF21 gene therapy as treatment for obesity and insulin resistance", EMBO MOLECULAR MEDICINE (ONLINE),Vol. 10, No. 8, 09 July 2018 (2018-07-09), page e8791,
XP055568532
1-16
abstract
p. 2 col. 1, 3rd §, p. 13 col. 2, 2nd §, p. 15 col. 2, last §, p. 19 col. 1, last §, p. 1 col. 2, 2nd §, p. 13 col. 2, 1st §, p. 13 col. 2, last §, p. 19 col. 2, 3rd §, p. 17 col. 1, 3rd §
(2)
Y
D. A. SARRUF ET AL, "Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats", DIABETES,Vol. 59, No. 7, 31 March 2010 (2010-03-31), page 1817-1824,
XP055568048
1-16
abstract
p. 1817 col. 2, 4th §, p. 1817 col. 2, 1st §, p. 1822 col. 1, 2nd §
(3)
Y
WO 2009120978 A2 (UNIV OHIO STATE [US]; DURING MATTHEW J [US]; CAO LEI [US]) 01 October 2009 (2009-10-01)
9
[00008], [00025], [00030], [000136], [000132], [00019], [00031], [00024], [00055], [00069]
(4)
Y
WO 2017201527 A2 (HARVARD COLLEGE [US]) 23 November 2017 (2017-11-23)
9
the whole document
sequences 51, 52, 136
(5)
Y
US 2018186849 A1 (MOHAMMADI MOOSA [US] ET AL) 05 July 2018 (2018-07-05)
9
sequences 236, 285, 294, 305, KH509732
the whole document
(6)
Y
WO 2011127337 A2 (OPKO CURNA LLC [US]; COLLARD JOSEPH [US]; KHORKOVA SHERMAN OLGA [US]) 13 October 2011 (2011-10-13)
9
sequence 1
the whole document
(7)
Y
WO 2017021893 A1 (NOVARTIS AG [CH]; YOWE DAVID LANGDON [US]) 09 February 2017 (2017-02-09)
9
sequences 1, 2
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2009120978 A2
01 October 2009
US 2011288160 A1
WO 2009120978 A2
24 November 2011
01 October 2009
WO 2017201527 A2
23 November 2017
AU 2017268469 A1
BR 112018073861 A2
CA 3025020 A1
CN 109844124 A
EP 3458585 A2
JP 2019519221 A
US 2019345224 A1
WO 2017201527 A2
03 January 2019
26 February 2019
23 November 2017
04 June 2019
27 March 2019
11 July 2019
14 November 2019
23 November 2017
US 2018186849 A1
05 July 2018
AU 2013271471 A1
CA 2875790 A1
CN 104736557 A
EP 2858663 A1
HK 1211607 A1
US 2013331316 A1
US 2014094406 A1
US 2017029480 A1
US 2018186849 A1
WO 2013184958 A1
15 January 2015
12 December 2013
24 June 2015
15 April 2015
27 May 2016
12 December 2013
03 April 2014
02 February 2017
05 July 2018
12 December 2013
WO 2011127337 A2
13 October 2011
CA 2795281 A1
CN 102858979 A
EP 2556160 A2
EP 3517613 A1
JP 5978203 B2
JP 2013523164 A
KR 20130048207 A
RU 2012142242 A
TW 201201818 A
US 2013035373 A1
US 2015225725 A1
US 2017355995 A1
WO 2011127337 A2
13 October 2011
02 January 2013
13 February 2013
31 July 2019
24 August 2016
17 June 2013
09 May 2013
20 May 2014
16 January 2012
07 February 2013
13 August 2015
14 December 2017
13 October 2011
WO 2017021893 A1
09 February 2017
AU 2016303545 A1
CA 2994516 A1
CN 108350072 A
EP 3331914 A1
JP 2018526988 A
KR 20180035852 A
RU 2018106642 A
WO 2017021893 A1
22 February 2018
09 February 2017
31 July 2018
13 June 2018
20 September 2018
06 April 2018
05 September 2019
09 February 2017
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
10 December 2019
Date of mailing of the international search report:
08 January 2020
Authorized officer:
Landré, Julien
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E